The inexpensive antidepressant fluvoxamine might help keep patients with Covid-19 from developing severe disease, according to a study published in The Lancet Global Health. Researchers found in another study that the coronavirus can infect cells of the inner ear, which may help explain the balance problems, hearing loss and tinnitus (ringing in the ears) experienced by some Covid-19 patients.
Texas A&M University Science Center, MD Anderson Cancer Center, and Pulmotect report that the drug PUL-042 appears to work against COVID-19 and other respiratory infections.
Covid-19 is slowly retreating across most of North, Central and South America, the Pan American Health Organization (PAHO) said on Oct. 27, reporting that last week the continent’s death and infection figures were the lowest in over a year.
Dupixent (dupilumab) scored the blockbuster medicine’s second study win in a week after Regeneron Pharmaceuticals and Sanofi revealed positive results from the second Phase III trial for the treatment of eosinophilic esophagitis (EoE).
The FDA’s outside expert panel will meet on November 30, 2021, to deliberate Merck’s pill for Covid-19 infection.
The Delta variant of the coronavirus does not appear to cause more severe disease in children than earlier forms of the virus, a UK study suggests. Another study found that in Covid-19 survivors, important components of the body’s immune response called memory B cells continue to evolve and get stronger for at least several months, producing highly potent antibodies that can neutralize new variants of the virus.
The U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of Takeda Pharmaceutical Company Limited’s maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease withgenotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.
The number of new Covid-19 infections dropped during the past month throughout the Americas, even though only 37 percent of the people in Latin America and the Caribbean are fully vaccinated, the Pan American Health Organization (PAHO) said on Oct. 6.
AstraZeneca Plc’s Covid-19 vaccine demonstrated 74 percent efficacy at preventing symptomatic disease, a figure that increased to 83.5 percent in people aged 65 and older, according to long-awaited results of the company’s U.S. clinical trial published on Sept. 29
French specialty vaccine company Valneva and U.S. drugmaker Pfizer reported positive results from the companies’ Phase II study on a vaccine candidate for Lyme disease.
